The 3D Printed Drugs Market is to Touch $225 Million by 2030; Growing demand for personalized medicine and Increasing deal with complex drug formulations propels market growth.

The 3D Printed Drugs Market size is estimated to reach $225 Million by 2030, growing at a CAGR of 11.5% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “3D Printed Drugs Market – By Dosage Form (Tablets, Capsules, Multi-drug Implants, Nanoparticles, Others), By Technology (Inkjet Printing, Fused Deposition Modeling, Stereolithography, Zip Dose Technology, Selective Laser Sintering (SLS), Others), By Application (Orthopedic, Neurology, Dental, Pediatrics and Geriatrics, Others), By End-User (Hospitals and Clinics, Research Laboratories, Academic, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”

Advancements in Bioprinting and Increasing demand for Innovative Drug Delivery Systems are expected to create growth opportunities in the market during forecast period.

North America accounted for the largest share of 48% of the 3D Printed Drugs Market in 2023 and is anticipated to experience the highest growth with a CAGR of 14.4% over the forecast period. North America has a high prevalence of chronic diseases and an aging population, increasing the demand for personalized and precise medication solutions that 3D printing can offer. The presence of leading technology companies and academic institutions also drives advancements in 3D printing technology, creating a conducive environment for market expansion. 

Developed by Aprecia Pharmaceuticals, ZipDose utilizes a proprietary 3D printing process known as powder-liquid 3DP to create rapidly disintegrating oral dosage forms. This technology allows for high-dose medications to be delivered in a single, easy-to-swallow tablet that disintegrates with just a sip of liquid. The advantages of ZipDose include precise dosing, improved patient adherence, and enhanced convenience, particularly for populations with swallowing difficulties, such as the elderly and pediatric patients. Furthermore, ZipDose was the first 3D printed drug technology to receive FDA approval, with its flagship product, Spritam (levetiracetam) which is approved in 2015 for the treatment of epilepsy. This milestone demonstrated the clinical viability and regulatory acceptance of 3D printed pharmaceuticals, positioning ZipDose as a leader in the market.

Conditions such as epilepsy, Parkinson's disease, and multiple sclerosis often require precise and personalized medication regimens to manage symptoms effectively. 3D printing technology allows for the customization of drug dosages and combinations tailored to each patient's unique needs, improving therapeutic outcomes. Moreover, the ability to print drugs with specific release profiles and intricate structures enhances the efficacy of treatments for neurological conditions. This technological advancement addresses the challenge of polypharmacy and the need for precise drug delivery, thereby driving the significant market share of 3D printed drugs in neurology.